A study, which polled more than 1,200 people, found that participants were less willing to book appointments when any type of AI use was indicated. More industry news is on the fund to bolster rural ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

These four dividend stocks are ideal choices for growth and income investors seeking reliable passive income with some growth potential.

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Health-care companies fell after a lackluster round of earnings. Shares of medical-device maker Abbott Labs shares tumbled by more than 8% after it trimmed and narrowed its 2025 growth projections ...

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...